150 related articles for article (PubMed ID: 26287147)
1. A Combined Molecular Docking/Dynamics Approach to Probe the Binding Mode of Cancer Drugs with Cytochrome P450 3A4.
Panneerselvam S; Yesudhas D; Durai P; Anwar MA; Gosu V; Choi S
Molecules; 2015 Aug; 20(8):14915-35. PubMed ID: 26287147
[TBL] [Abstract][Full Text] [Related]
2. Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.
Liu XJ; Lu H; Sun JX; Wang SR; Mo YS; Yang XS; Shi BK
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):465-8. PubMed ID: 25737032
[TBL] [Abstract][Full Text] [Related]
3. Computational Investigation of Ligand Binding to the Peripheral Site in CYP3A4: Conformational Dynamics and Inhibitor Discovery.
Du H; Li J; Cai Y; Zhang H; Liu G; Tang Y; Li W
J Chem Inf Model; 2017 Mar; 57(3):616-626. PubMed ID: 28221037
[TBL] [Abstract][Full Text] [Related]
4. Differential Interactions of Cytochrome P450 3A5 and 3A4 with Chemotherapeutic Agent-Vincristine: A Comparative Molecular Dynamics Study.
Saba N; Bhuyan R; Nandy SK; Seal A
Anticancer Agents Med Chem; 2015; 15(4):475-83. PubMed ID: 25634447
[TBL] [Abstract][Full Text] [Related]
5. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
Saba N; Seal A
J Mol Model; 2018 Mar; 24(4):82. PubMed ID: 29502215
[TBL] [Abstract][Full Text] [Related]
6. Molecular Dynamics Simulation Framework to Probe the Binding Hypothesis of CYP3A4 Inhibitors.
Kiani YS; Ranaghan KE; Jabeen I; Mulholland AJ
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510073
[TBL] [Abstract][Full Text] [Related]
7. Spectroscopic studies and molecular docking on the interaction of organotin antitumor compound bis[2,4-difluoro-N-(hydroxy-⟨κ⟩O)benzamidato-⟨κ⟩O]diphenyltin(IV) with human cytochrome P450 3A4 protease.
Wei Y; Niu L; Liu X; Zhou H; Dong H; Kong D; Li Y; Li Q
Spectrochim Acta A Mol Biomol Spectrosc; 2016 Jun; 163():154-61. PubMed ID: 27049867
[TBL] [Abstract][Full Text] [Related]
8. Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer.
Subhani S; Jamil K
Biomed Pharmacother; 2015 Jul; 73():65-74. PubMed ID: 26211584
[TBL] [Abstract][Full Text] [Related]
9. Enzyme Kinetics and Molecular Docking Studies on Cytochrome 2B6, 2C19, 2E1, and 3A4 Activities by Sauchinone.
Gong EC; Chea S; Balupuri A; Kang NS; Chin YW; Choi YH
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498658
[TBL] [Abstract][Full Text] [Related]
10. Binding Specificity Determines the Cytochrome P450 3A4 Mediated Enantioselective Metabolism of Metconazole.
Zhuang S; Zhang L; Zhan T; Lu L; Zhao L; Wang H; Morrone JA; Liu W; Zhou R
J Phys Chem B; 2018 Jan; 122(3):1176-1184. PubMed ID: 29310431
[TBL] [Abstract][Full Text] [Related]
11. Theoretical Insights into Imidazolidine Oxidation of Imidacloprid by Cytochrome P450 3A4.
Zheng ML; Li CR; Bai QH; Xiao H; Hu W; Xue Y; Gao JY
J Mol Graph Model; 2018 Mar; 80():173-181. PubMed ID: 29414036
[TBL] [Abstract][Full Text] [Related]
12. A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs.
Mannu J; Jenardhanan P; Mathur PP
J Mol Model; 2011 Aug; 17(8):1847-54. PubMed ID: 21080015
[TBL] [Abstract][Full Text] [Related]
13. Insights into regioselective metabolism of mefenamic acid by cytochrome P450 BM3 mutants through crystallography, docking, molecular dynamics, and free energy calculations.
Capoferri L; Leth R; ter Haar E; Mohanty AK; Grootenhuis PD; Vottero E; Commandeur JN; Vermeulen NP; Jørgensen FS; Olsen L; Geerke DP
Proteins; 2016 Mar; 84(3):383-96. PubMed ID: 26757175
[TBL] [Abstract][Full Text] [Related]
14. Analysis of binding modes of ligands to multiple conformations of CYP3A4.
Teixeira VH; Ribeiro V; Martel PJ
Biochim Biophys Acta; 2010 Oct; 1804(10):2036-45. PubMed ID: 20601222
[TBL] [Abstract][Full Text] [Related]
15. Elucidating substrate promiscuity in the human cytochrome 3A4.
Hayes C; Ansbro D; Kontoyianni M
J Chem Inf Model; 2014 Mar; 54(3):857-69. PubMed ID: 24571781
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of drug-drug interactions mediated by human cytochrome P450 CYP3A4 monomer.
Denisov IG; Grinkova YV; Baylon JL; Tajkhorshid E; Sligar SG
Biochemistry; 2015 Apr; 54(13):2227-39. PubMed ID: 25777547
[TBL] [Abstract][Full Text] [Related]
17. Conformational dynamics of CYP3A4 demonstrate the important role of Arg212 coupled with the opening of ingress, egress and solvent channels to dehydrogenation of 4-hydroxy-tamoxifen.
Shahrokh K; Cheatham TE; Yost GS
Biochim Biophys Acta; 2012 Oct; 1820(10):1605-17. PubMed ID: 22677141
[TBL] [Abstract][Full Text] [Related]
18. Flavokawain A inhibits Cytochrome P450 in in vitro metabolic and inhibitory investigations.
Niu L; Ding L; Lu C; Zuo F; Yao K; Xu S; Li W; Yang D; Xu X
J Ethnopharmacol; 2016 Sep; 191():350-359. PubMed ID: 27318274
[TBL] [Abstract][Full Text] [Related]
19. Structural and energetic analysis to provide insight residues of CYP2C9, 2C11 and 2E1 involved in valproic acid dehydrogenation selectivity.
Bello M; Mendieta-Wejebe JE; Correa-Basurto J
Biochem Pharmacol; 2014 Jul; 90(2):145-58. PubMed ID: 24794636
[TBL] [Abstract][Full Text] [Related]
20. Concurrent cooperativity and substrate inhibition in the epoxidation of carbamazepine by cytochrome P450 3A4 active site mutants inspired by molecular dynamics simulations.
Müller CS; Knehans T; Davydov DR; Bounds PL; von Mandach U; Halpert JR; Caflisch A; Koppenol WH
Biochemistry; 2015 Jan; 54(3):711-21. PubMed ID: 25545162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
